$BIOLQ
BIOLASE, INC Stock $biolq

$biolq Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000095017022004115 Filed on March 17, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q1
Revenue	$10.17M	$12.41M	$8.116M
YoY Change	25.26%	45.63%	69.68%
Cost Of Revenue	$5.437M	$7.502M	$5.375M
YoY Change	1.15%	8.41%	56.71%
Gross Profit	$4.729M	$4.906M	$2.741M
YoY Change	72.53%	204.72%	102.59%
Gross Profit Margin	46.52%	39.54%	33.77%
Selling, General & Admin	$7.391M	$7.669M	$6.911M
YoY Change	6.95%	25.93%	20.95%
% of Gross Profit	156.29%	156.32%	252.13%
Research & Development	$1.544M	$1.542M	$1.803M
YoY Change	-14.36%	46.86%	81.94%
% of Gross Profit	32.65%	31.43%	65.78%
Depreciation & Amortization	$117.0K	$119.0K	$85.00K
YoY Change	37.65%	-496.67%	-51.98%
% of Gross Profit	2.47%	2.43%	3.1%
Operating Expenses	$8.935M	$9.211M	$8.803M
YoY Change	1.5%	29.01%	31.29%
Operating Profit	-$4.206M	-$4.305M	-$6.062M
YoY Change	-30.62%	-22.15%	13.27%
Interest Expense	-$433.0K	-$777.0K	-$575.0K
YoY Change	-24.7%	46.6%	-197.62%
% of Operating Profit
Other Income/Expense, Net	-$553.0K	$0.00	-$779.0K
YoY Change	-29.01%	-100.0%	-215.75%
Pretax Income	-$4.759M	-$5.207M	-$6.841M
YoY Change	-30.43%	-14.08%	13.54%
Income Tax	$17.00K	$72.00K	$60.00K
% Of Pretax Income
Net Earnings	-$4.776M	-$5.279M	-$6.901M
YoY Change	-30.79%	-14.02%	14.9%
Net Earnings / Revenue	-46.98%	-42.55%	-85.03%
Basic Earnings Per Share	-$0.81		-$0.06
Diluted Earnings Per Share	-$775.5K	-$859.5K	-$0.06
COMMON SHARES
Basic Shares Outstanding	154.3M	153.3M	134.6M
Diluted Shares Outstanding	6.159M		134.6M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.61M	$29.97M	$40.84M
YoY Change	-47.1%	70.68%	2604.64%
Cash & Equivalents	$21.60M	$30.00M	$40.84M
Short-Term Investments
Other Short-Term Assets	$2.386M	$1.332M	$1.760M
YoY Change	35.57%	132.46%	15.79%
Inventory	$14.61M	$12.93M	$11.88M
Prepaid Expenses
Receivables	$5.200M	$4.200M	$3.300M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$43.78M	$49.35M	$57.75M
YoY Change	-24.18%	40.57%	189.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.244M	$1.067M	$693.0K
YoY Change	79.51%	36.45%	-39.74%
Goodwill	$2.900M	$2.900M	$2.900M
YoY Change	0.0%	-0.89%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$231.0K	$220.0K	$226.0K
YoY Change	2.21%	-4.76%	-53.31%
Total Long-Term Assets	$6.459M	$5.930M	$5.735M
YoY Change	12.62%	0.25%	25.74%
TOTAL ASSETS
Total Short-Term Assets	$43.78M	$49.35M	$57.75M
Total Long-Term Assets	$6.459M	$5.930M	$5.735M
Total Assets	$50.24M	$55.28M	$63.48M
YoY Change	-20.86%	34.76%	158.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.643M	$3.309M	$3.072M
YoY Change	51.14%	24.82%	-24.26%
Accrued Expenses	$6.027M	$8.276M	$600.0K
YoY Change	904.5%	24.13%	-85.29%
Deferred Revenue	$2.442M	$2.259M	$1.961M
YoY Change	24.53%	18.58%	-1.06%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$0.00	$0.00	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$13.11M	$13.84M	$11.27M
YoY Change	16.34%	23.35%	-52.41%
LONG-TERM LIABILITIES
Long-Term Debt	$13.67M	$13.60M	$16.30M
YoY Change	-16.13%	-15.96%
Other Long-Term Liabilities	$387.0K	$330.0K	$77.00K
YoY Change	402.6%	-68.75%	-93.04%
Total Long-Term Liabilities	$14.05M	$13.93M	$16.37M
YoY Change	-14.16%	-19.19%	1378.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.11M	$13.84M	$11.27M
Total Long-Term Liabilities	$14.05M	$13.93M	$16.37M
Total Liabilities	$29.64M	$30.08M	$29.97M
YoY Change	-1.09%	-2.97%	17.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$272.3M	-$267.5M	-$258.3M
YoY Change	5.43%	6.43%	7.37%
Common Stock	$293.6M	$293.3M	$292.3M
YoY Change	0.44%	12.1%	23.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.60M	$25.21M	$33.52M
YoY Change
Total Liabilities & Shareholders Equity	$50.24M	$55.28M	$63.48M
YoY Change	-20.86%	34.76%	158.79%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q1
OPERATING ACTIVITIES
Net Income	-$4.776M	-$5.279M	-$6.901M
YoY Change	-30.79%	-14.02%	14.9%
Depreciation, Depletion And Amortization	$117.0K	$119.0K	$85.00K
YoY Change	37.65%	-496.67%	-51.98%
Cash From Operating Activities	-$8.021M	-$3.104M	-$6.499M
YoY Change	23.42%	129.93%	57.21%
INVESTING ACTIVITIES
Capital Expenditures	$304.0K	-$311.0K	$8.000K
YoY Change	3700.0%	1455.0%	-11.11%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$304.0K	-$311.0K	-$8.000K
YoY Change	3700.0%	1455.0%	-11.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$4.800M		$13.30M
YoY Change	-63.91%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	68.00K	29.83M
YoY Change	-100.0%	-236.0%	-25591.45%
NET CHANGE
Cash From Operating Activities	-8.021M	-3.104M	-6.499M
Cash From Investing Activities	-304.0K	-311.0K	-8.000K
Cash From Financing Activities	0.000	68.00K	29.83M
Net Change In Cash	-8.366M	-3.347M	23.17M
YoY Change	-136.11%	135.7%	-641.61%
FREE CASH FLOW
Cash From Operating Activities	-$8.021M	-$3.104M	-$6.499M
Capital Expenditures	$304.0K	-$311.0K	$8.000K
Free Cash Flow	-$8.325M	-$2.793M	-$6.507M
YoY Change	27.94%	110.0%	57.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement
CY2019	biol	Proceeds From Sale Of Preferred Stock ProceedsFromSaleOfPreferredStock
CY2021	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses
CY2019	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims
CY2019	biol	Payments Of Warrant Issuance Costs In Financing Activities PaymentsOfWarrantIssuanceCostsInFinancingActivities
CY2019	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness
CY2019	biol	Issuance Of Restricted Shares IssuanceOfRestrictedShares
CY2020	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt
CY2019	biol	Principal Payment On Term Loan PrincipalPaymentOnTermLoan
CY2019	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses
CY2019	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	biol	Patent Litigation Mark To Market PatentLitigationMarkToMarket
CY2020	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement
CY2019	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0
CY2019	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2019	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment
CY2019	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2019	biol	Effective Income Tax Rate Reconciliation Expired Net Operating Loss Carryforwards EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards
CY2019	biol	Receivable From Warrants Exercised And Included In Prepaid And Other Current Assets ReceivableFromWarrantsExercisedAndIncludedInPrepaidAndOtherCurrentAssets
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2019	biol	Proceeds From Sale Of Common Stock Warrants ProceedsFromSaleOfCommonStockWarrants
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0000811240
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-36385
CY2021	dei	Entity Registrant Name EntityRegistrantName	BIOLASE, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0442441
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	27042 Towne Centre Drive
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 270
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Lake Forest
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92610
CY2021	dei	City Area Code CityAreaCode	949
CY2021	dei	Local Phone Number LocalPhoneNumber	361-1200
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	103837004
CY2021	dei	Security12b Title Security12bTitle	Common stock, par value $0.001 per share
CY2021	dei	Trading Symbol TradingSymbol	BIOL
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	154340703
CY2021	dei	Auditor Firm AuditorFirmId	243
CY2021	dei	Auditor Name AuditorName	BDO USA, LLP
CY2021	dei	Auditor Location AuditorLocation	Costa Mesa, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29972000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17564000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	203000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	312000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2154000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4017000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4238000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3059000
CY2021Q4	us-gaap	Inventory Net InventoryNet	12929000
CY2020Q4	us-gaap	Inventory Net InventoryNet	11157000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2012000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3018000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	49354000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	35110000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1067000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	782000
CY2021Q4	us-gaap	Goodwill Goodwill	2926000
CY2020Q4	us-gaap	Goodwill Goodwill	2926000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1717000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1976000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	220000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	231000
CY2021Q4	us-gaap	Assets Assets	55284000
CY2020Q4	us-gaap	Assets Assets	41025000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3309000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2651000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8276000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6667000
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2259000
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1905000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13844000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11223000
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	329000
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	374000
CY2021Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	521000
CY2020Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	384000
CY2021Q4	us-gaap	Mediumterm Notes Noncurrent MediumtermNotesNoncurrent	13603000
CY2020Q4	us-gaap	Mediumterm Notes Noncurrent MediumtermNotesNoncurrent	16186000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1449000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1774000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	330000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1056000
CY2021Q4	us-gaap	Liabilities Liabilities	30076000
CY2020Q4	us-gaap	Liabilities Liabilities	30997000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	18000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	18000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	34000
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	118000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	180000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	180000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	153721000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97709000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	153676000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97663000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	154000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	98000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	293177000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	261573000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-623000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-385000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-267534000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-251376000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	25208000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	10028000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55284000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41025000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39188000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22780000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37799000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	22659000
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	16607000
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	23511000
CY2021	us-gaap	Gross Profit GrossProfit	16529000
CY2020	us-gaap	Gross Profit GrossProfit	6173000
CY2019	us-gaap	Gross Profit GrossProfit	14288000
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	15339000
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11242000
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14396000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11258000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9772000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10748000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6048000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3695000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4765000
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-315000
CY2021	us-gaap	Operating Expenses OperatingExpenses	32960000
CY2020	us-gaap	Operating Expenses OperatingExpenses	24709000
CY2019	us-gaap	Operating Expenses OperatingExpenses	29909000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-16431000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-18536000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-15621000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	452000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	21000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	121000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2224000
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2359000
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2157000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3014000
CY2020	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	4215000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-338000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1835000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2278000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16093000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16701000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17899000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	128000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-44000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-16158000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-16829000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-17855000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-238000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	316000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-31000
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	377000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3798000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16396000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16513000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17886000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-16158000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-16829000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-17855000
CY2021	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	546000
CY2020	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	17378000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16704000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-34207000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17855000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
CY2021	biol	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	147746000
CY2020	biol	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	61136000
CY2019	biol	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	23201000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	11089000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000
CY2019	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	4250000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2395000
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	364000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	161000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-17855000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-31000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	856000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	67000
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	163000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2591000
CY2020	biol	Stock Issued During Period Value Common Stock Warrants Exercised StockIssuedDuringPeriodValueCommonStockWarrantsExercised	1544000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-16829000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	316000
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	10028000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13291000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	132000
CY2021	biol	Issuance Of Common Stock For Settlement Of Liability IssuanceOfCommonStockForSettlementOfLiability	510000
CY2021	biol	Issuance Of Restricted Shares During Period Value IssuanceOfRestrictedSharesDuringPeriodValue	164000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2416000
CY2021	biol	Stock Issued During Period Value Common Stock Warrants Exercised StockIssuedDuringPeriodValueCommonStockWarrantsExercised	15063000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-16158000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-238000
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	25208000
CY2021	us-gaap	Profit Loss ProfitLoss	-16158000
CY2020	us-gaap	Profit Loss ProfitLoss	-16829000
CY2019	us-gaap	Profit Loss ProfitLoss	-17855000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	499000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	982000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-202000
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1328000
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1695000
CY2021	biol	Provision For Sales Returns ProvisionForSalesReturns	0
CY2020	biol	Provision For Sales Returns ProvisionForSalesReturns	87000
CY2019	biol	Provision For Sales Returns ProvisionForSalesReturns	0
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	-275000
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	-591000
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	413000
CY2021	biol	Inventory Write Offs And Disposals InventoryWriteOffsAndDisposals	122000
CY2020	biol	Inventory Write Offs And Disposals InventoryWriteOffsAndDisposals	-1300000
CY2019	biol	Inventory Write Offs And Disposals InventoryWriteOffsAndDisposals	-15000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	159000
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	165000
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	140000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	356000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	331000
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	188000
CY2021	biol	Patent Litigation Mark To Market PatentLitigationMarkToMarket	315000
CY2020	biol	Patent Litigation Mark To Market PatentLitigationMarkToMarket	0
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5850000
CY2021	biol	Issuance Of Restricted Shares IssuanceOfRestrictedShares	164000
CY2020	biol	Issuance Of Restricted Shares IssuanceOfRestrictedShares	0
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1641000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1662000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	3370000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	2742000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3014000
CY2021	biol	Gain Loss On Issuance Of Warrants To Consultants GainLossOnIssuanceOfWarrantsToConsultants	0
CY2020	biol	Gain Loss On Issuance Of Warrants To Consultants GainLossOnIssuanceOfWarrantsToConsultants	0
CY2019	biol	Gain Loss On Issuance Of Warrants To Consultants GainLossOnIssuanceOfWarrantsToConsultants	-48000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	7000
CY2021	biol	Earned Interest Income EarnedInterestIncome	0
CY2020	biol	Earned Interest Income EarnedInterestIncome	0
CY2019	biol	Earned Interest Income EarnedInterestIncome	-2000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	978000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4286000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-655000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1375000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	871000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-825000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-285000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-825000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-439000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1765000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2107000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3156000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	308000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-379000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	114000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16710000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12795000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12746000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	707000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	96000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	207000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-707000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-96000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-207000
CY2021	biol	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	14420000
CY2020	biol	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	6912000
CY2019	biol	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	9171000
CY2021	biol	Proceeds From Sale Of Preferred Stock ProceedsFromSaleOfPreferredStock	0
CY2020	biol	Proceeds From Sale Of Preferred Stock ProceedsFromSaleOfPreferredStock	2700000
CY2021	biol	Proceeds From Sale Of Common Stock Warrants ProceedsFromSaleOfCommonStockWarrants	0
CY2020	biol	Proceeds From Sale Of Common Stock Warrants ProceedsFromSaleOfCommonStockWarrants	15300000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1135000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1281000
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	821000
CY2021	biol	Payments Of Warrant Issuance Costs In Financing Activities PaymentsOfWarrantIssuanceCostsInFinancingActivities	0
CY2020	biol	Payments Of Warrant Issuance Costs In Financing Activities PaymentsOfWarrantIssuanceCostsInFinancingActivities	1640000
CY2021	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0
CY2020	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	3140000
CY2021	biol	Proceeds From Issuance Of Term Loan ProceedsFromIssuanceOfTermLoan	0
CY2020	biol	Proceeds From Issuance Of Term Loan ProceedsFromIssuanceOfTermLoan	0
CY2019	biol	Proceeds From Issuance Of Term Loan ProceedsFromIssuanceOfTermLoan	2500000
CY2021	biol	Principal Payment On Term Loan PrincipalPaymentOnTermLoan	0
CY2020	biol	Principal Payment On Term Loan PrincipalPaymentOnTermLoan	700000
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	3000000
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	3000000
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	25000
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	128000
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	133000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	16562000
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	46000
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	132000
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12299000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11775000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2255000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17876000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6101000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8356000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30175000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17876000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29954000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24349000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10721000
CY2021	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-238000
CY2020	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	317000
CY2019	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-23000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1771000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6101000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1881000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	1784000
CY2021	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	56000
CY2020	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	11000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	171000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	22000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	35000
CY2021	biol	Cash Paid For Operating Leases CashPaidForOperatingLeases	246000
CY2020	biol	Cash Paid For Operating Leases CashPaidForOperatingLeases	489000
CY2019	biol	Cash Paid For Operating Leases CashPaidForOperatingLeases	797000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	18000
CY2021	biol	Non Cash Settlement Of Performance Award Liability NonCashSettlementOfPerformanceAwardLiability	510000
CY2020	biol	Non Cash Settlement Of Performance Award Liability NonCashSettlementOfPerformanceAwardLiability	151000
CY2019	biol	Non Cash Settlement Of Performance Award Liability NonCashSettlementOfPerformanceAwardLiability	201000
CY2021	biol	Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation	48000
CY2020	biol	Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation	2037000
CY2019	biol	Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation	276000
CY2021	biol	Non Cash Equity Financing Costs In Accounts Payable NonCashEquityFinancingCostsInAccountsPayable	0
CY2020	biol	Non Cash Equity Financing Costs In Accounts Payable NonCashEquityFinancingCostsInAccountsPayable	74000
CY2019	biol	Non Cash Equity Financing Costs In Accounts Payable NonCashEquityFinancingCostsInAccountsPayable	129000
CY2021	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	546000
CY2020	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	17378000
CY2021	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0
CY2020	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	10000
CY2021	biol	Receivable From Warrants Exercised And Included In Prepaid And Other Current Assets ReceivableFromWarrantsExercisedAndIncludedInPrepaidAndOtherCurrentAssets	-1498000
CY2020	biol	Receivable From Warrants Exercised And Included In Prepaid And Other Current Assets ReceivableFromWarrantsExercisedAndIncludedInPrepaidAndOtherCurrentAssets	1498000
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	67000
CY2019	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	161000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-16400000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-18500000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-15600000
CY2021Q4	biol	Working Capital WorkingCapital	35500000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30000000.0
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4200000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13300000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	16600000
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13300000
CY2020	biol	Refundable Payroll Tax Credit RefundablePayrollTaxCredit	0.50
	biol	Increased Credit IncreasedCredit	0.70
CY2021Q4	biol	Amount Received For Employee Retention Credit AmountReceivedForEmployeeRetentionCredit	1800000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	200000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	300000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29972000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17564000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	203000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	312000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30175000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17876000
CY2021	us-gaap	Depreciation Depreciation	400000
CY2020	us-gaap	Depreciation Depreciation	500000
CY2019	us-gaap	Depreciation Depreciation	1000000.0
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2019	biol	Convertible Preferred Shares Issuable To Number Of Equity Stockholders ConvertiblePreferredSharesIssuableToNumberOfEquityStockholders	2
CY2021	biol	Revenue From Products And Services Transferred To Customers Percentage RevenueFromProductsAndServicesTransferredToCustomersPercentage	0.88
CY2020	biol	Revenue From Products And Services Transferred To Customers Percentage RevenueFromProductsAndServicesTransferredToCustomersPercentage	0.81
CY2019	biol	Revenue From Products And Services Transferred To Customers Percentage RevenueFromProductsAndServicesTransferredToCustomersPercentage	0.81
CY2021	biol	Revenue From Services Transferred To Customers Over Time Percentage RevenueFromServicesTransferredToCustomersOverTimePercentage	0.12
CY2020	biol	Revenue From Services Transferred To Customers Over Time Percentage RevenueFromServicesTransferredToCustomersOverTimePercentage	0.19
CY2019	biol	Revenue From Services Transferred To Customers Over Time Percentage RevenueFromServicesTransferredToCustomersOverTimePercentage	0.19
CY2021Q4	biol	Contract With Customer Liability In Undelivered Elements ContractWithCustomerLiabilityInUndeliveredElements	800000
CY2020Q4	biol	Contract With Customer Liability In Undelivered Elements ContractWithCustomerLiabilityInUndeliveredElements	700000
CY2021Q4	biol	Contract With Customer Liability In Undelivered Elements ContractWithCustomerLiabilityInUndeliveredElements	835000
CY2020Q4	biol	Contract With Customer Liability In Undelivered Elements ContractWithCustomerLiabilityInUndeliveredElements	670000
CY2021Q4	biol	Contract With Customer Liability In Extended Warranty Contracts ContractWithCustomerLiabilityInExtendedWarrantyContracts	1753000
CY2020Q4	biol	Contract With Customer Liability In Extended Warranty Contracts ContractWithCustomerLiabilityInExtendedWarrantyContracts	1609000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2588000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2279000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	329000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	374000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2259000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1905000
CY2021	biol	Contract With Customer Liability Revenue Recognized Extended Warranty ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty	1100000
CY2021	biol	Contract With Customer Liability Revenue Recognized Undelivered Elements ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements	600000
CY2020	biol	Contract With Customer Liability Revenue Recognized Undelivered Elements ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements	300000
CY2020	biol	Contract With Customer Liability Revenue Recognized Extended Warranty ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty	2000000.0
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39188000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22780000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37799000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39188000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22780000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37799000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39188000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22780000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37799000
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1132000
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1110000
CY2018Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1308000
CY2021	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	1747000
CY2020	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	1047000
CY2019	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	806000
CY2021	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1793000
CY2020	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1025000
CY2019	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1004000
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1086000
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1132000
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1110000
CY2021Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	521000
CY2020Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	384000
CY2019Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	245000
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	565000
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	748000
CY2019Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	865000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	1400000
CY2020	us-gaap	Advertising Expense AdvertisingExpense	600000
CY2019	us-gaap	Advertising Expense AdvertisingExpense	500000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1700000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3400000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2700000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1662000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3370000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2742000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	800000
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1000000.0
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.11
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.03
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.85
CY2021	biol	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend	0
CY2020	biol	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend	0
CY2019	biol	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.010
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.004
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.026
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57700000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52200000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23200000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	61100000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6900000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2200000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	4000000.0
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1067000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	782000
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3969000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3552000
CY2021Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	805000
CY2020Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	0
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	405000
CY2020Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	885000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4444000
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3721000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1726000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1158000
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6759000
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6278000
CY2021Q4	us-gaap	Inventory Net InventoryNet	12929000
CY2020Q4	us-gaap	Inventory Net InventoryNet	11157000
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1000000.0
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	800000
CY2021	biol	Write Downs For Excess And Obsolete Inventory Expense WriteDownsForExcessAndObsoleteInventoryExpense	300000
CY2020	biol	Write Downs For Excess And Obsolete Inventory Expense WriteDownsForExcessAndObsoleteInventoryExpense	1300000
CY2019	biol	Write Downs For Excess And Obsolete Inventory Expense WriteDownsForExcessAndObsoleteInventoryExpense	15000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	680000
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	947000
CY2021Q4	biol	Receivable For Warrants Exercised ReceivableForWarrantsExercised	0
CY2020Q4	biol	Receivable For Warrants Exercised ReceivableForWarrantsExercised	1498000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1332000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	573000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2012000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3018000
CY2021Q4	biol	Property Plant And Equipment Gross Excluding Land PropertyPlantAndEquipmentGrossExcludingLand	8952000
CY2020Q4	biol	Property Plant And Equipment Gross Excluding Land PropertyPlantAndEquipmentGrossExcludingLand	8269000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8049000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7664000
CY2021Q4	biol	Property Plant And Equipment Net Excluding Land PropertyPlantAndEquipmentNetExcludingLand	903000
CY2020Q4	biol	Property Plant And Equipment Net Excluding Land PropertyPlantAndEquipmentNetExcludingLand	605000
CY2021Q4	us-gaap	Land Land	164000
CY2020Q4	us-gaap	Land Land	177000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	275000
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	565000
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	748000
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	558000
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	165000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	281000
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	600000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	305000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1099000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	731000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8276000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6667000
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2020	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2019	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2021Q4	us-gaap	Goodwill Goodwill	2900000
CY2020Q4	us-gaap	Goodwill Goodwill	2900000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2800000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2800000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2800000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2800000
CY2021	biol	Indefinite Lived Intangible Assets Useful Life IndefiniteLivedIntangibleAssetsUsefulLife	indefinite life
CY2020	biol	Indefinite Lived Intangible Assets Useful Life IndefiniteLivedIntangibleAssetsUsefulLife	indefinite life
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	2926000
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	2926000
CY2021Q4	us-gaap	Goodwill Goodwill	2926000
CY2020Q4	us-gaap	Goodwill Goodwill	2926000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	17000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	26000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	23000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	47000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	101000
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	73000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	64000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	127000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	96000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-0
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-12000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	1000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	1000
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-128000
CY2021	biol	Deferred Income Tax Expense Benefit Adjustment DeferredIncomeTaxExpenseBenefitAdjustment	1000
CY2020	biol	Deferred Income Tax Expense Benefit Adjustment DeferredIncomeTaxExpenseBenefitAdjustment	1000
CY2019	biol	Deferred Income Tax Expense Benefit Adjustment DeferredIncomeTaxExpenseBenefitAdjustment	-140000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	128000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-44000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.342
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.068
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.350
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.070
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.006
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.006
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.021
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.042
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.041
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.024
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.097
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.200
CY2021	biol	Effective Income Tax Rate Reconciliation Expired Net Operating Loss Carryforwards EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards	-0
CY2020	biol	Effective Income Tax Rate Reconciliation Expired Net Operating Loss Carryforwards EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards	-0.037
CY2021	biol	Effectiveincometaxratereconciliationeffectofprioryeartrue Ups EffectiveincometaxratereconciliationeffectofprioryeartrueUps	0.043
CY2020	biol	Effectiveincometaxratereconciliationeffectofprioryeartrue Ups EffectiveincometaxratereconciliationeffectofprioryeartrueUps	0.228
CY2019	biol	Effectiveincometaxratereconciliationeffectofprioryeartrue Ups EffectiveincometaxratereconciliationeffectofprioryeartrueUps	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.011
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.007
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.026
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.004
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.007
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-38000
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-38000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves	1903000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves	2094000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	640000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	139000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	903000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	939000
CY2020Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	3000
CY2021Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	5000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3429000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3333000
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	771000
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	858000
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	192000
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	166000
CY2021Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	105000
CY2020Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	105000
CY2021Q4	biol	Deferred Tax Assets Disallowed Interest DeferredTaxAssetsDisallowedInterest	1757000
CY2020Q4	biol	Deferred Tax Assets Disallowed Interest DeferredTaxAssetsDisallowedInterest	1128000
CY2021Q4	biol	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	462000
CY2020Q4	biol	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	518000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	48843000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	44345000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	58972000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	53590000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57679000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52161000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1293000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1429000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	664000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	664000
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	428000
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	492000
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	144000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	221000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1236000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1377000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	57000
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	52000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57700000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3900000
CY2020	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	3900000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	194900000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	201200000
CY2021	biol	Operating Loss Carryforwards Expirations Period OperatingLossCarryforwardsExpirationsPeriod	2038
CY2021	biol	Net Operating Loss Amount Utilized NetOperatingLossAmountUtilized	0
CY2020	biol	Net Operating Loss Amount Utilized NetOperatingLossAmountUtilized	0
CY2021	biol	Deferred Tax Assets Research And Development Credits Amount Utilized DeferredTaxAssetsResearchAndDevelopmentCreditsAmountUtilized	0
CY2020	biol	Deferred Tax Assets Research And Development Credits Amount Utilized DeferredTaxAssetsResearchAndDevelopmentCreditsAmountUtilized	0
CY2021	us-gaap	Payments For Rent PaymentsForRent	900000
CY2020	us-gaap	Payments For Rent PaymentsForRent	700000
CY2021	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Description LesseeOperatingLeaseLeaseNotYetCommencedDescription	the only lease that had not commenced was for the additional facility lease in Corona, California
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	610000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	624000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	609000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	489000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2332000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	509000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	509000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	509000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	159000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	350000
CY2021	biol	Current Inome Related To Global Intangible Low Taxed Income CurrentInomeRelatedToGlobalIntangibleLowTaxedIncome	0
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-847000
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-1244000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	13603000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	16186000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	13603000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16186000
CY2021Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.120
CY2021Q4	biol	Long Term Debt Maturities Repayments Of Interest In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfInterestInNextTwelveMonths	1494000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2100000
CY2021Q4	biol	Long Term Debt Maturities Repayments Of Interest In Year Two LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo	1440000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2800000
CY2021Q4	biol	Long Term Debt Maturities Repayments Of Interest In Year Three LongTermDebtMaturitiesRepaymentsOfInterestInYearThree	1170000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	9401000
CY2021Q4	biol	Long Term Debt Maturities Repayments Of Interest In Year Four LongTermDebtMaturitiesRepaymentsOfInterestInYearFour	1858000
CY2021Q4	biol	Long Term Debt Maturities Repayments Of Principal After Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour	149000
CY2021Q4	biol	Long Term Debt Maturities Repayments Of Interest In Year After Four LongTermDebtMaturitiesRepaymentsOfInterestInYearAfterFour	89000
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	14450000
CY2021Q4	biol	Long Term Debt Maturities Repayments Of Interest LongTermDebtMaturitiesRepaymentsOfInterest	6051000
CY2021Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P1Y
CY2021	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2025-12-31
CY2020Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2020Q1	biol	Lease Facility Area LeaseFacilityArea	11000
CY2020Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2020-07-01
CY2021Q4	biol	Lease Facility Area LeaseFacilityArea	15000
CY2021Q4	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2025-06-30
CY2020Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P66M
CY2020Q1	biol	Lease Facility Area LeaseFacilityArea	12000
CY2020Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2020-07-01
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	246000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	489000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	150000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1976000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	478000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1854000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	405000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	305000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1449000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1774000
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.123
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.123
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1854000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2079000
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14000000
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	1000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	180000000
CY2019	us-gaap	Payments For Rent PaymentsForRent	800000
CY2021Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	18700000
CY2021Q1	biol	Litigation Settlement Shares Issued LitigationSettlementSharesIssued	500000
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	600000
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.03
CY2021Q1	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	14400000
CY2019Q4	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	4200000
CY2020Q2	biol	Allocated To Warrants Based Upon Fair Values AllocatedToWarrantsBasedUponFairValues	3900000
CY2021	us-gaap	Dividends Dividends	0
CY2020	us-gaap	Dividends Dividends	0
CY2019	us-gaap	Dividends Dividends	0
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2020Q2	biol	Other Offering Expenses OtherOfferingExpenses	700000
	biol	Warrants Adjusted Exercise Price WarrantsAdjustedExercisePrice	0.60
CY2019Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.5750
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1623000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.54
CY2019	biol	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue	90000
CY2019	biol	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue	1.74
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.10
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	424000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	9.73
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1287000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.77
CY2020	biol	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue	1258000
CY2020	biol	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue	0.38
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	147000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.87
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2398000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.96
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	53000
CY2021	biol	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue	70000
CY2021	biol	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue	0.80
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	352000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.38
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	378000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.17
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1738000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.48
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	15000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1613000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.60
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	14000
CY2021	biol	Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod	342000
CY2021	biol	Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriodWeightedAverageExercisePrice	7.57
CY2021Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1738000
CY2021Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	2.48
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y1M6D
CY2021Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1613000
CY2021Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	2.60
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	132000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	82000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.66
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.29
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.51
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	404000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	227000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	587000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1067000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	782000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1193000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39188000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22780000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37799000

Files In Submission

Name	View Source	Status
0000950170-22-004115-index-headers.html	Edgar Link	pending
0000950170-22-004115-index.html	Edgar Link	pending
0000950170-22-004115.txt	Edgar Link	pending
0000950170-22-004115-xbrl.zip	Edgar Link	pending
biol-20211231.htm	Edgar Link	pending
biol-20211231.xsd	Edgar Link	pending
biol-20211231_cal.xml	Edgar Link	unprocessable
biol-20211231_def.xml	Edgar Link	unprocessable
biol-20211231_htm.xml	Edgar Link	completed
biol-20211231_lab.xml	Edgar Link	unprocessable
biol-20211231_pre.xml	Edgar Link	unprocessable
biol-ex10_32.htm	Edgar Link	pending
biol-ex21_1.htm	Edgar Link	pending
biol-ex23_1.htm	Edgar Link	pending
biol-ex31_1.htm	Edgar Link	pending
biol-ex32_1.htm	Edgar Link	pending
biol-ex4_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIOLQ
BIOLASE, INC Stock $biolq

2022 Q1 Form 10-K Financial Statement

#000095017022004115 Filed on March 17, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIOLQ BIOLASE, INC Stock $biolq

2022 Q1 Form 10-K Financial Statement

#000095017022004115 Filed on March 17, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIOLQ
BIOLASE, INC Stock $biolq